Literature DB >> 17627814

Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women.

F Labrie1, A Bélanger, C Labrie, B Candas, L Cusan, J L Gomez.   

Abstract

To study the bioavailability of dehydroepiandrosterone (DHEA) administered by the oral and percutaneous routes, three groups of 12 postmenopausal women aged 60-70 years received two capsules of 50mg of DHEA orally before breakfast daily for 14 days or applied 4 g of a 10% DHEA cream or gel at the same time of the day on a 30 cm x 30 cm surface area on the thighs. Detailed serial blood sampling over 24h was performed following 1st and 14th DHEA administration for measurement of DHEA and nine of its metabolites by liquid chromatography tandem mass spectrometry (LC-MS/MS) or gas chromatography mass spectrometry (GC-MS). Serum levels of estrone (E1) and estradiol (E2) did not change following DHEA administration by any of the three formulations, while serum androstenedione (4-dione), testosterone, DHEA sulfate (DHEA-S), E(1)-S, androsterone glucuronide (ADT-G) and 3alpha-androstanediol-G (3alpha-diol-G), increased in all cases, the effect on these parameters being more important after oral than percutaneous administration due to the metabolism of DHEA into these metabolites in the gastrointestinal tract and liver. No qualitative differences in DHEA metabolism are observed between the oral and percutaneous routes of DHEA administration while the levels of all steroids remain on a plateau during the 24h period during chronic percutaneous DHEA administration. The present data show that DHEA is transformed into active androgens and estrogens in peripheral intracrine tissues with no or minimal release of the active steroids E(1), E(2) or testosterone in the circulation. Moreover, DHEA is preferentially transformed into androgens rather than into estrogens. Most importantly, the present data show that changes in serum DHEA following oral or percutaneous DHEA administration are not a valid parameter of DHEA action since the increase in serum DHEA is at least 100% greater than the increase in the formation of active androgens and estrogens and thus much higher than the potential physiological effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627814     DOI: 10.1016/j.jsbmb.2007.02.007

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

1.  Cognition in aged rhesus monkeys: effect of DHEA and correlation with steroidogenic gene expression.

Authors:  K G Sorwell; L Renner; A R Weiss; M Neuringer; S G Kohama; H F Urbanski
Journal:  Genes Brain Behav       Date:  2016-11-24       Impact factor: 3.449

Review 2.  Genetics of androgen metabolism in women with infertility and hypoandrogenism.

Authors:  Aya Shohat-Tal; Aritro Sen; David H Barad; Vitaly Kushnir; Norbert Gleicher
Journal:  Nat Rev Endocrinol       Date:  2015-05-05       Impact factor: 43.330

3.  Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol, a synthetic anti-inflammatory androstene.

Authors:  Clarence N Ahlem; Michael R Kennedy; Theodore M Page; Christopher L Reading; Steven K White; John J McKenzie; Phaedra I Cole; Dwight R Stickney; James M Frincke
Journal:  Int J Clin Exp Med       Date:  2011-04-23

4.  Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens.

Authors:  Catherine M Jankowski; Wendolyn S Gozansky; John M Kittelson; Rachael E Van Pelt; Robert S Schwartz; Wendy M Kohrt
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

5.  Bioanalytical LC-MS Method for the Quantification of Plasma Androgens and Androgen Glucuronides in Breast Cancer.

Authors:  Eleni Kalogera; Constantinos Pistos; Xeni Provatopoulou; Costas A Christophi; George C Zografos; Maria Stefanidou; Chara Spiliopoulou; Sotirios Athanaselis; Antonia Gounaris
Journal:  J Chromatogr Sci       Date:  2016-01-12       Impact factor: 1.618

6.  Oral dehydroepiandrosterone might prevent frequent tears in atrophic skin: A case report.

Authors:  Harry W Daniell
Journal:  JAAD Case Rep       Date:  2017-11-06

7.  Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration.

Authors:  Chrysanthi Tsika; Manolis N Tzatzarakis; Sophia G Antimisiaris; Pavlina Tsoka; Paschalis Efstathopoulos; Ioannis Charalampopoulos; Achille Gravanis; Miltiadis K Tsilimbaris
Journal:  Pharmacol Res Perspect       Date:  2021-04

8.  Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.

Authors:  Elisabetta Pietri; Ilaria Massa; Sara Bravaccini; Sara Ravaioli; Maria Maddalena Tumedei; Elisabetta Petracci; Caterina Donati; Alessio Schirone; Federico Piacentini; Lorenzo Gianni; Mario Nicolini; Enrico Campadelli; Alessandra Gennari; Alessandro Saba; Beatrice Campi; Linda Valmorri; Daniele Andreis; Francesco Fabbri; Dino Amadori; Andrea Rocca
Journal:  Oncologist       Date:  2018-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.